News

Kineta's KVA12123 to Be Showcased at SITC Annual Meeting

Kineta's KVA12123 to Be Showcased at SITC Annual Meeting

Kineta to Present KVA12123 at SITC 2024

Kineta, Inc. (OTC: KANT), a dedicated biotechnology firm focused on pioneering immunotherapies aimed at overcoming cancer immune resistance, has exciting news to share. The company announced that its abstract on the clinical program of KVA12123 has received acceptance for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. The event is set to take place from November 6-10, 2024, and will be available both in-person and virtually.

Details on the Presentation of KVA12123

Dr. Thierry Guillaudeux, the Chief Scientific Officer of Kineta, revealed that the poster will be presented on November 8, featuring new clinical data from an ongoing Phase 1/2 trial. This trial focuses on KVA12123, Kineta's immunotherapy that blocks VISTA, administered alone and in combination with Merck's KEYTRUDA (pembrolizumab). This research highlights the potential of KVA12123 in treating advanced solid tumors, showcasing the collaboration between Kineta and leading research institutes.

Presentation Title and Authors

The title of the presentation is "A Phase 1/2 Clinical Trial of antiVISTA – KVA12123 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors." It lists a talented team of authors including Dr. Jason T. Henry and esteemed colleagues from various prestigious institutions. Their collective expertise contributes significantly to the insights shared in this trial.

Abstract Information

The abstract number is 625. Attendees can look forward to engaging discussions from 9:00 AM to 7:00 PM Central Time on the said date, hosted in the Exhibit Halls AB at the George R. Brown Convention Center. More information regarding the abstract titles will be accessible on the SITC website soon. Additionally, Kineta plans to provide access to the poster content on its website following the conference.

About Kineta and Its Mission

Kineta operates with a steadfast commitment to transforming patient lives through innovative immunotherapies. The company draws on its extensive knowledge in innate immunity, actively working on groundbreaking therapies to tackle significant challenges present in current cancer treatment methods. At present, Kineta's pipeline includes KVA12123 and a promising preclinical monoclonal antibody targeting CD27.

KVA12123: A Game Changer in Cancer Therapy

Through unique binding properties and a refined IgG1 Fc region, KVA12123 has shown impressive tumor growth inhibition both independently and in synergy with established checkpoint inhibitors in preclinical studies. This innovative approach intends to mitigate immune suppression within the tumor microenvironment, complementing traditional T cell-focused therapies. Preliminary research indicates KVA12123's potential effectiveness in a variety of cancers such as non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and more.

Recent Developments at Kineta

In early 2024, Kineta underwent a significant corporate restructuring aimed at reducing expenditures while preserving financial resources. This decision resulted in a workforce reduction and the temporary halt of enrolling new patients in the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123. Kineta is actively exploring strategic alternatives to enhance stockholder value.

Contact Information for Inquiries

For further inquiries, interested parties can reach out to Kineta's Investor Relations at info@kineta.us. The company is keen to connect and provide additional insights into their ongoing research and vision for the future.

Frequently Asked Questions

What is KVA12123?

KVA12123 is a VISTA blocking immunotherapy developed by Kineta, currently in clinical trials targeting advanced solid tumors.

When will the poster for KVA12123 be presented?

The poster will be presented on November 8, 2024, at the SITC Annual Meeting.

What phase is the clinical trial for KVA12123 currently in?

KVA12123 is currently in Phase 1/2 of clinical trials, evaluating its efficacy and safety.

Who is presenting the KVA12123 poster at SITC?

Dr. Jason Henry from Sarah Cannon Research Institute will be presenting the poster featuring new clinical data.

How can I learn more about Kineta?

You can visit their official website at www.kinetabio.com for further information regarding their research and developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

American Savings Bank IPO Hits NYSE: $129M Raised

Updated Category News Views 12

A Big Day for American Savings Bank Buckled up yet? Because American Savings Bank has just shot onto the NYSE, raising a hefty $129 million. A solid start, I’d say, for a Honolulu-based outfit that now struts around with a valuation tipping beyond $1.03 billion. That’s what you get when you price more than eight million shares at $16 a pop. NYSE:ASBH is the new kid on...

Continue Reading
B2B Growth Hinges on Narrative Coherence, Study Shows

Updated Category News Views 6

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Continue Reading
Jacob Walthour to Be Honored for Economic Leadership

Updated Category News Views 7

The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...

Continue Reading
Propensity Rockets to No. 70 on the 2026 Inc. 5000 List

Updated Category News Views 6

Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...

Continue Reading
Koogler's Sale to ALL4: A Game-Changer for the Southeast

Updated Category News Views 6

A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...

Continue Reading
Finastra Recognized as 2026 Leader in Payment Platforms

Updated Category News Views 5

Finastra Steals the Spotlight in Payments Innovation When it comes to the modern world of finance, nothing screams ‘adapt or fade into oblivion’ like the payments industry. Well, here’s a reality check from QKS Group: Finastra has snatched the spotlight in their SPARK Matrix™ for 2026 as a powerhouse in integrated bank payments platforms. Clearly, this ain’t...

Continue Reading
Medicare Competitive Bidding May Slash Jobs, Access

Updated Category News Views 5

Medicare's New Program: Potential Knockout Punch? Today, we dive into Medicare's latest shake-up that might just be the unseen wrecking ball swinging toward thousands of jobs and small businesses in the healthcare sector. Two years from now, starting January 2028, the Competitive Bidding Program is set to reroute the entire landscape for suppliers of key medical products...

Continue Reading
Ransoms and Mega-Losses Surge in Cyber Claims Study

Updated Category News Views 5

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Continue Reading
Goddess Maintenance Co. Eyes BeautyMatter Award

Updated Category News Views 5

Challenging the Haircare Norm with Confidence Goddess Maintenance Co. doesn't just draft a fresh play in the beauty industry playbook—it's ripping out the old pages and setting a new standard. This ain't your granny's haircare game anymore, folks. They're up for a 2026 BeautyMatter Award, a nod to their gut-busting innovation in the conditioner category with their star...

Continue Reading
Solar Fencing Revolutionizes North Texas Homes

Updated Category News Views 5

Fences Go Solar: Welcome to the Future Land of fences and sunshine, North Texas is about to see a game changer in home improvement. Southwest Fence & Deck is rolling out the red carpet as an Authorized SOL Fence Installation Partner, putting solar power right in your backyard. Yeah, there have been sparks of innovation in plenty of fields, but who expected fences to join...

Continue Reading

Top 5 Most Recently Viewed Articles

StateHouse Holdings Faces Bankruptcy in U.S. and Canada Markets

Updated Category News Views 190

Status Update on StateHouse Holdings Inc. StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF) finds itself in a challenging position as it announces its entry into bankruptcy under Canada’s Bankruptcy and Insolvency Act. This decision was reached after extensive discussions concerning its financial health and obligations. Reason...

Continue Reading
Delisting and Deregistration Plans Announced by Pixie Dust Technologies

Updated Category News Views 264

Understanding Pixie Dust Technologies' Delisting Plans Pixie Dust Technologies, Inc. has recently made a significant announcement regarding its American Depositary Receipts (ADRs) and their future on the NASDAQ Capital Market. After considerable discussions, the company’s board of directors has resolved to delist its ADRs, a bold move that highlights its strategic shift...

Continue Reading
Investors Target Class Action Against Ibotta, Inc. – IBTA News

Updated Category News Views 191

Investors Alert for Ibotta, Inc. Class Action Lawsuit Pomerantz LLP has recently announced a significant class action lawsuit against Ibotta, Inc. (NYSE: IBTA), a company that has attracted considerable attention from investors. Anyone who has experienced losses on their investment in Ibotta is encouraged to get involved and make their voices heard during this legal...

Continue Reading
Innovative Payment Solution for Students: Trust Bank and TerraPay

Updated Category News Views 380

Revolutionizing International Payments for Students Through a transformative partnership, Trust Bank and TerraPay have introduced a groundbreaking international payment solution aimed at Bangladeshi students pursuing education abroad. Recognizing the complexities of financial transactions associated with studying outside the country, this initiative is designed to provide...

Continue Reading
Pillsbury Winthrop Shaw Pittman Joins Texas Nuclear Initiative

Updated Category News Views 123

Pillsbury Winthrop Shaw Pittman Expands Impact in Nuclear Energy The Texas Nuclear Alliance (TNA) has proudly announced the inclusion of Pillsbury Winthrop Shaw Pittman as a Founding Member. In Texas, this is the only industry association focused on fostering the development of nuclear technology. A Forward Step for Texas Nuclear Development Pillsbury Winthrop Shaw...

Continue Reading